Compugen Ltd.
Company & revenue
About Compugen Ltd.
Who they are
Compugen Ltd., an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and product candidates. Its operations extend across Israel, the United States, and Europe. The company’s core activities center around its immuno-oncology pipeline, which includes several investigational treatments: COM701, an anti-PVRIG antibody currently undergoing Phase I clinical studies for solid tumors.
Customer concentrationPREMIUM
The company does not disclose specific customer names or concentration percentages in its recent filings, noting that its business is comprised of one operating segment focused on the research, development, and commercialization of therapeutic candidates.
Business relationships & partnershipsPREMIUM
Detailed revenue, brand and relationship research has not yet been completed for CGEN.
Sources
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
76
Strong
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
58
Fair
Financial Strength
65
Business Quality / Moat
37
Management
100
Growth Quality
48
Risk / Durability
15
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
79
Fair
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
76/100
Building Historical Record
Model Score 76/100 — estimates relative performance potential, distinct from WallStreetScore (company quality).
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
WSS currently rates the company as financially and fundamentally strong.
At today’s price, the WSS valuation framework currently reads as relatively attractive.
The model outlook is currently positive.
- •Strong overall Company Strength score
- •Asset quality scores strongly
- •Valuation scores attractively
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for CGEN
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can CGEN maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is CGEN's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •How is CGEN likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •Is CGEN's valuation discount tied to a temporary concern or to a longer-term business risk?
Essential Investment Snapshot
Wall Street Score
76
Opportunity Score
79
Market Cap
$218.4M
P/E Ratio
6.3
EPS
$0.38
52-Week High
$3.24
52-Week Low
$1.43
Beta
2.79
Intrinsic Value
$14.45
Analyst Target
$5.00
Shares Outstanding
93.8M
Total Revenue
$74.0M
Total Debt
$3.0M
Dividend
No current dividend
Liquidation Value / Share
$0.95
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Weakening momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Community Sentiment
0 active · 0 total callsNo personal call yet on CGEN.
What the Bulls Say
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Material partnership/catalyst: Collaboration and license agreement involving the development of rilvegostomig, with a recent monetization of a portion of future royalties.
- +Material partnership/catalyst: Collaboration and license agreement for the development of GS-0321 (formerly COM902).
- +Product opportunity: Compugen Ltd., an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and product candidates. Its operations extend across Israel, the United States, and Europe. The company’s core activities center around its immuno-oncology pipeline, which includes several investigational treatments: COM701, an anti-PVRIG antibody currently undergoing Phase I clinical studies for solid t.
What the Bears Say
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
Bull and bear cases summarize disclosed catalysts, growth opportunities and risks; they are not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
5 historical score records availablePrevious Score
75
Sep 14, 2026
Change
+0.2
points
Current Score
76
Oct 1, 2026
Category Changes
CGEN increased 0.2 points because overall fundamentals improved.
Projected Score
Projected Score
79
Projected Change
+3.6%
Preliminary comparable-period financial changes suggest improvement of approximately 3.6 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
UndervaluedCurrent Price
$2.31
Intrinsic Value
$14.45
Difference
−$12.14
-84.0% vs IV
Margin of Safety
84.0%
Related Companies
BiotechnologyNews
Compugen (NASDAQ:CGEN) versus MiMedx Group (NASDAQ:MDXG) Head-To-Head Comparison
Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
All You Need to Know About Compugen (CGEN) Rating Upgrade to Buy
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial